Abstract:BackgroundTarget identification and validation is a pressing challenge in the pharmaceutical industry, with many of the programmes that fail for efficacy reasons showing poor association between the drug target and the disease. Computational prediction of successful targets could have a considerable impact on attrition rates in the drug discovery pipeline by significantly reducing the initial search space. Here, we explore whether gene–disease association data from the Open Targets platform is sufficient to predict therapeutic targets that are actively being pursued by pharmaceutical companies or are already on the market.MethodsTo test our hypothesis, we train four different classifiers (a random forest, a support vector machine, a neural network and a gradient boosting machine) on partially labelled data and evaluate their performance using nested cross-validation and testing on an independent set. We then select the best performing model and use it to make predictions on more than 15,000 genes. Finally, we validate our predictions by mining the scientific literature for proposed therapeutic targets.ResultsWe observe that the data types with the best predictive power are animal models showing a disease-relevant phenotype, differential expression in diseased tissue and genetic association with the disease under investigation. On a test set, the neural network classifier achieves over 71% accuracy with an AUC of 0.76 when predicting therapeutic targets in a semi-supervised learning setting. We use this model to gain insights into current and failed programmes and to predict 1431 novel targets, of which a highly significant proportion has been independently proposed in the literature.ConclusionsOur in silico approach shows that data linking genes and diseases is sufficient to predict novel therapeutic targets effectively and confirms that this type of evidence is essential for formulating or strengthening hypotheses in the target discovery process. Ultimately, more rapid and automated target prioritisation holds the potential to reduce both the costs and the development times associated with bringing new medicines to patients.

AI-powered therapeutic target discovery

AI approaches for the discovery and validation of drug targets

Artificial intelligence and drug discovery

Elucidating the Role of Artificial Intelligence in Drug Development from the Perspective of Drug-Target Interactions

Artificial Intelligence for Drug Discovery: Are We There Yet?

Piquing artificial intelligence towards drug discovery: Tools, techniques, and applications

The Role of Artificial Intelligence in Drug Discovery and Development

From understanding diseases to drug design: can artificial intelligence bridge the gap?

Comprehensive applications of the artificial intelligence technology in new drug research and development

Artificial intelligence in drug discovery: recent advances and future perspectives

Artificial Intelligence for Drug Discovery: Resources, Methods, and Applications

Artificial Intelligence in Pharmaceutical Sciences

Artificial intelligence as a tool in drug discovery and development

Employing Artificial Intelligence Methods in Drug Development: A New Era in Medicine

AI for targeted polypharmacology: The next frontier in drug discovery

The potential applications of artificial intelligence in drug discovery and development

AI-based Computational Methods in Early Drug Discovery and Post Market Drug Assessment: A Survey

Artificial intelligence and machine learning‐aided drug discovery in central nervous system diseases: State‐of‐the‐arts and future directions

In silico prediction of novel therapeutic targets using gene–disease association data

Artificial intelligence revolutionizing drug development: Exploring opportunities and challenges

Artificial intelligence in cancer target identification and drug discovery